Bayer withdrew its patent lawsuit against Teva Pharmaceutical Industries for allegedly infringing Bayer’s Yaz contraceptive with its Gianvi generic, according to court documents. Report
Original Source of Bayer backs off Teva’s premature Yaz copy
Abbott Laboratories doesn’t plan to hold onto Solvay’s flu vaccine business. The company started marketing the unit last week, sources tell the Wall Street Journal , by sending out materials to several large healthcare companies. The business could fetch some €500 million, or $619 million. Abbott bought Solvay’s drugs…
Did financial ties to drugmaker AstraZeneca ( NYSE: AZN ) prejudice researchers in the pivotal trial that showed its cholesterol fighter Crestor prevented heart disease? An article in the new Archives of Internal Medicine raises that question, pointing out that nine of the 14 researchers who ran the Jupiter…
In a blow to Eli Lilly’s ( NYSE: LLY ) hopes for the new blood thinner Effient , a new study has tied the drug to an increased risk of cancer. The researchers analyzed unpublished data from a study that was key to FDA approval–Triton-Timi 38, which pitted Effient…
Imagine Avandia safety as an old-fashioned balance scale. Data on one side upholding the contention that the benefits of the GlaxoSmithKline ( NYSE: GSK )
AstraZeneca and Medicines for Malaria Venture (MMV) announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca’s extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant…
Social media is fraught with potential pitfalls for pharma brand managers. But, as the new FiercePharma e-book Social Media for Pharma Brand Managers
The pharmaceutical industry continues to rely heavily on sales from an aging portfolio of drugs, whilst the proportion of total sales from newer drugs has dropped, according to data released today from the 2010 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business. Release
Original Source of…
Are investors too gloomy about Big Pharma? A new article in Barron’s suggests that’s the case. Despite worries about the coming patent cliff–which will claim some of the industry’s biggest drugs, such as Lipitor and Singulair–as well as what new drugs might fill the gaps, the pharma business doesn’t…
AstraZeneca ( NYSE: AZN )